Article

False-positive and false-negative rates in meconium drug testing.

US Drug Testing Laboratories, Chicago, IL 60612, USA.
Clinical Chemistry (Impact Factor: 7.77). 12/1995; 41(11):1614-6.
Source: PubMed

ABSTRACT To determine the number of false-negative results produced by inefficient extraction of drugs from meconium, three published procedures were compared by using previously confirmed positive and negative meconium specimens. The methods were not equivalent in their ability to extract drugs from the matrix. To determine the number of false positives reported by the use of screen-only (unconfirmed) results, 535 screen-positive meconium specimens were subjects to confirmation by gas chromatography-mass spectrometry. Fifty-seven percent of the samples were confirmed positive for one or more of the drugs under investigation, showing that a false-positive rate as high as 43% may exist when unconfirmed screening results are used.

1 Bookmark
 · 
515 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The objective of this study is to review and summarize available evidence regarding the impact of amphetamines on pregnancy, the newborn infant and the child. Amphetamines are neurostimulants and neurotoxins that are some of the most widely abused illicit drugs in the world. Users are at high risk of psychiatric co-morbidities, and evidence suggests that perinatal amphetamine exposure is associated with poor pregnancy outcomes, but data is confounded by other adverse factors associated with drug-dependency. Data sources are Government data, published articles, conference abstracts and book chapters. The global incidence of perinatal amphetamine exposure is most likely severely underestimated but acknowledged to be increasing rapidly, whereas exposure to other drugs, for example, heroin, is decreasing. Mothers known to be using amphetamines are at high risk of psychiatric co-morbidity and poorer obstetric outcomes, but their infants may escape detection, because the signs of withdrawal are usually less pronounced than opiate-exposed infants. There is little evidence of amphetamine-induced neurotoxicity and long-term neurodevelopmental impact, as data is scarce and difficult to extricate from the influence of other factors associated with children living in households where one or more parent uses drugs in terms of poverty and neglect. Perinatal amphetamine-exposure is an increasing worldwide concern, but robust research, especially for childhood outcomes, remains scarce. We suggest that exposed children may be at risk of ongoing developmental and behavioral impediment, and recommend that efforts be made to improve early detection of perinatal exposure and to increase provision of early-intervention services for affected children and their families.
    Journal of perinatology: official journal of the California Perinatal Association 05/2012; 32(10):737-47. · 1.59 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Urine is the most widely used specimen for the detection of and analysis of abused drugs. However, commonly abused drugs can only be detected 1–3 days after abuse using urine specimens. Urine collection, for forensic purposes, requires a special collection facility. Despite strict rules for specimen collection, due to privacy issues in urine collection, sample adulteration is not uncommon. The other matrices provide solutions to some of these problems and have additional advantages for drug testing programs. Hair analysis provides non-invasive and supervised sample collection with the largest window of drug detection period (>90 days). Oral fluid analysis provides a convenient way of sample collection under direct supervision and is useful in assessing very recent drug use. The sweat drug analysis provides continuous monitoring of drug use for several weeks. Meconium is a good specimen for detection of intrauterine drug exposure. Despite many advantages, these matrices pose special challenges, particularly analytical and interpretation of results.
    05/2007: pages 337-364;
  • Clinical Pharmacokinetics 07/1996; 31(1). · 5.49 Impact Factor

Full-text

Download
16 Downloads
Available from